PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2- breast cancer.
Terán E, Lozano R, Rodríguez CA, Abad M, Figuero L, Muñoz JA, Cigarral B, Rodrígues A, Sancho M, Gómez MA, Morchón D, Montero JC, Sayagués JM, Ludeña MD, Fonseca E.
Terán E, et al. Among authors: sayagues jm.
Cancer Med. 2024 Sep;13(17):e70101. doi: 10.1002/cam4.70101.
Cancer Med. 2024.
PMID: 39235099
Free PMC article.